In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $10.00. The company's shares closed last Thursday at $3.19. According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -33.0% and a 20.4% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Clarus Therapeutics Holdings, and Galmed Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $14.33 average price target, representing a 356.4% upside.
https://www.tipranks.com/news/blurbs/viking-therapeutics-vktx-receives-a-buy-from-maxim-group?utm_source=advfn.com&utm_medium=referral
Viking Therapeutics (NASDAQ:VKTX)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Viking Therapeutics Charts.
Viking Therapeutics (NASDAQ:VKTX)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Viking Therapeutics Charts.